---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000103"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2024-01-29T23:59:59+00:00"
generated_at: "2026-06-06T15:44:38.849598+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics approves 1-for-15 reverse stock split effective Jan 31, 2024

## Summary
- Reverse split ratio of 1-for-15 approved by Board on Jan 29, 2024; effective Jan 31 at 5:00 PM ET.
- Every 15 pre-split shares combine into 1 post-split share; trading begins on split-adjusted basis Feb 1 under same symbol TCRT with new CUSIP.
- Stockholders authorized split ratio range (1-for-5 to 1-for-15) at June 2023 annual meeting; Board selected 1-for-15 on Jan 12, 2024.
- Equiniti Trust Company appointed as exchange agent for the reverse split.

## SEC filing metadata
- accession: 0001193805-24-000103
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2024-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119380524000103/0001193805-24-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119380524000103/e619210_8k-at.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000103
- JSON: https://secwatch.observer/filing/0001193805-24-000103.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.